The America Invents Act (AIA) has had a profound impact on patent litigation, particularly surrounding inter partes and other post-grant proceedings. Below, Manish K. Mehta, who handles patent litigation across an array of key sectors, including pharmaceuticals, discusses both the defensive and offensive strategies that companies can employ in the rapidly evolving patent arena. His remarks have been edited for length and style.

MCC: As an IP litigator you represent companies ranging across sectors, from life sciences to manufacturing. Are the changes to the patent laws, particularly the introduction of inter partes review proceedings, having different impacts on different sectors?

Originally published in Corporate Counsel on May 17, 2016.